Universal gut microbiome-derived signature predicts cirrhosis

by University of California - San DiegoIllustration depicts a healthy liver (left) and a liver with cirrhosis. Credit: National Institute of Diabetes and Digestive and Kidney DiseasesNonalcoholic

Updated on: May 28,2024 7

Universal gut microbiome-derived signature predicts cirrhosis

by University of California - San DiegoIllustration depicts a healthy liver (left) and a liver with cirrhosis. Credit: National Institute of Diabetes and Digestive and Kidney DiseasesNonalcoholic

Updated on:May 28,2024 7

Assessing the mechanisms for liver fibrosis

by First Hospital of Jilin UniversityHepatocyte-mediated activation of HSC, the innate and adaptive immune activation in the metabolic syndrome. Soluble mediators are in red. Credit: Wajahat MehalChro

Updated on: May 28,2024 8

Assessing the mechanisms for liver fibrosis

by First Hospital of Jilin UniversityHepatocyte-mediated activation of HSC, the innate and adaptive immune activation in the metabolic syndrome. Soluble mediators are in red. Credit: Wajahat MehalChro

Updated on:May 28,2024 8

Gut microbiota harnessed as tool to diagnose diseases, promising results for fatty liver diagnosis

by University of JyväskyläThe diversity of the gut microbiota in the low (n = 25) and high (n = 37) liver fat groups. (A) Shannon index, a measure of alpha-diversity indicating species diversity.

Updated on: May 29,2024 4

Gut microbiota harnessed as tool to diagnose diseases, promising results for fatty liver diagnosis

by University of JyväskyläThe diversity of the gut microbiota in the low (n = 25) and high (n = 37) liver fat groups. (A) Shannon index, a measure of alpha-diversity indicating species diversity.

Updated on:May 29,2024 4

Immune therapies against chronic hepatitis B

by Ehime UniversityTwo main types of immune therapies have been employed to treat chronic hepatitis B during the last 4 decades. However, it seems that HBV-antigen-specific immune therapy may be safe

Updated on: May 29,2024 7

Immune therapies against chronic hepatitis B

by Ehime UniversityTwo main types of immune therapies have been employed to treat chronic hepatitis B during the last 4 decades. However, it seems that HBV-antigen-specific immune therapy may be safe

Updated on:May 29,2024 7

Two-organ chip developed to answer fatty liver questions

by Kyoto UniversityThe interaction between the small intestine and the liver of patients with non-alcoholic fatty liver disease (NAFLD) has been reproduced on a small chip. Credit: Mindy Takamiya

Updated on: May 29,2024 6

Two-organ chip developed to answer fatty liver questions

by Kyoto UniversityThe interaction between the small intestine and the liver of patients with non-alcoholic fatty liver disease (NAFLD) has been reproduced on a small chip. Credit: Mindy Takamiya

Updated on:May 29,2024 6

Maddening itch of liver disease comes from a surprising source

by Duke University School of NursingExcess lipids produced by liver failure signal an itching sensation directly to the skin cells, through a receptor called TRPV4 and a microRNA. Credit: Wolfgan

Updated on: May 29,2024 4

Maddening itch of liver disease comes from a surprising source

by Duke University School of NursingExcess lipids produced by liver failure signal an itching sensation directly to the skin cells, through a receptor called TRPV4 and a microRNA. Credit: Wolfgan

Updated on:May 29,2024 4

New standards to quantify hepatitis B virus reservoirs in liver cells

by Nicola Wittekindt, Deutsches Zentrum für InfektionsforschungThe effect of different DNA extraction methods on cccDNA quantification by qPCR and SB in HBV-infected USG mouse liver tissue. (A) Schema

Updated on: May 29,2024 7

New standards to quantify hepatitis B virus reservoirs in liver cells

by Nicola Wittekindt, Deutsches Zentrum für InfektionsforschungThe effect of different DNA extraction methods on cccDNA quantification by qPCR and SB in HBV-infected USG mouse liver tissue. (A) Schema

Updated on:May 29,2024 7

Using social determinants of health to guide liver disease screening

by Ariana Baldassano,Rush University Medical CenterCredit:JHEP Reports(2023). DOI: 10.1016/j.jhepr.2023.100696Black people face a higher risk of developing severe liver fibrosis, but

Updated on: May 29,2024 8

Using social determinants of health to guide liver disease screening

by Ariana Baldassano,Rush University Medical CenterCredit:JHEP Reports(2023). DOI: 10.1016/j.jhepr.2023.100696Black people face a higher risk of developing severe liver fibrosis, but

Updated on:May 29,2024 8

Inosine is a promising metabolite for enhancing mitochondrial function and cellular potency

Updated on: May 29,2024 0

Inosine is a promising metabolite for enhancing mitochondrial function and cellular potency

Updated on:May 29,2024 0

Popular diabetes drug may also reduce the risk of severe liver disease

by Karolinska InstitutetCredit: Pixabay/CC0 Public DomainOzempic and other GLP1 agonists are associated with a reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes

Updated on: June 01,2024 6

Popular diabetes drug may also reduce the risk of severe liver disease

by Karolinska InstitutetCredit: Pixabay/CC0 Public DomainOzempic and other GLP1 agonists are associated with a reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes

Updated on:June 01,2024 6

Scientists find omega-3 lysolipids may prevent fatty liver disease

by Duke-NUS Medical SchoolDetection of the lysolipid transporter Mfsd2a in hepatocytes, stained green, in proximity to a bile duct, stained magenta. Credit: Chin Cheen FeiLong-running research by

Updated on: June 03,2024 8

Scientists find omega-3 lysolipids may prevent fatty liver disease

by Duke-NUS Medical SchoolDetection of the lysolipid transporter Mfsd2a in hepatocytes, stained green, in proximity to a bile duct, stained magenta. Credit: Chin Cheen FeiLong-running research by

Updated on:June 03,2024 8

Study shows seladelpar beneficial for patients with primary biliary cholangitis

by Elana GotkineFor patients with primary biliary cholangitis, more receiving the peroxisome proliferator-activated receptor delta (PPARδ) agonist seladelpar have a biochemical response and alkaline p

Updated on: June 04,2024 6

Study shows seladelpar beneficial for patients with primary biliary cholangitis

by Elana GotkineFor patients with primary biliary cholangitis, more receiving the peroxisome proliferator-activated receptor delta (PPARδ) agonist seladelpar have a biochemical response and alkaline p

Updated on:June 04,2024 6